Acute treatment (3 days in vivo) in both subtypes resulted in significant reductions in the levels of SHH pathway genes (Supplementary Fig. S2A), indicating that on-target, therapeutic dosing of LDE225 was achieved in both tumor subtypes. The gene discussed is SHH; the disease is neoplasm.